<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01609296</url>
  </required_header>
  <id_info>
    <org_study_id>10048613</org_study_id>
    <nct_id>NCT01609296</nct_id>
  </id_info>
  <brief_title>IN.PACT Global Clinical Study</brief_title>
  <official_title>The IN.PACT Global Clinical Study for the Treatment of Comprehensive Superficial Femoral and/or Popliteal Artery Lesions Using the IN.PACT Admiral™ Drug-Eluting Balloon.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect safety and efficacy data on the IN.PACT Admiral™ Drug&#xD;
      Eluting Balloon (DEB) in treatment of atherosclerotic disease in the superficial femoral&#xD;
      and/or popliteal arteries in a &quot;real world&quot; patient population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral artery disease (PAD) commonly results from progressive narrowing of the arteries&#xD;
      in the lower extremities, usually due to atherosclerosis. Progression of PAD can result in&#xD;
      critical limb ischemia (CLI), manifested by ischemic pain at rest or in the breakdown of the&#xD;
      skin, resulting in ulcers or gangrene which ultimately may lead to amputation and death.&#xD;
&#xD;
      The IN.PACT Global Clinical Study aims to expand and understand the safety and efficacy data&#xD;
      on the IN.PACT Admiral™ DEB in a real world population of subjects with intermittent&#xD;
      claudication and/or rest pain (Rutherford class 2-3-4) due to obstructive disease of the&#xD;
      superficial femoral and/or popliteal arteries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">January 17, 2020</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Cohort ITT - Primary Effectiveness Endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from clinically-driven target lesion revascularization (TLR) within 12 months post-index procedure, which is defined as: • Any re-intervention within the target lesion(s) due to symptoms or drop of ABI ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Cohort ITT - Primary Safety Endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>A composite of freedom from device- and procedure-related mortality through 30 days, freedom from major target limb amputation and TLR within 12 months post-index procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Imaging Cohort ITT - Primary Effectiveness Endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Primary Patency within 12 months post-index procedure, which is defined as:&#xD;
Freedom from clinically-driven TLR and&#xD;
Freedom from restenosis as determined by DUS Peak Systolic Velocity Ratio (PSVR) ≤ 2.4.&#xD;
Restenosis determined by either PSVR &gt;2.4 as assessed by an independent DUS core lab or &gt;50% stenosis as assessed by an independent angiographic core lab.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>150mm DEB ITT Cohort - Primary Effectiveness Endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from clinically-driven target lesion revascularization (TLR) within 12 months post-index procedure, which is defined as:&#xD;
• Any re-intervention within the target lesion(s) due to symptoms or drop of ABI ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - MAEs</measure>
    <time_frame>12 months</time_frame>
    <description>MAE (Major Adverse Events) is defined as all-cause mortality, clinically-driven TVR (Target Vessel Revascularization), major target limb amputation, thrombosis at the target lesion site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - TLR</measure>
    <time_frame>12 months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - TVR</measure>
    <time_frame>12 months.</time_frame>
    <description>Any Target vessel revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Device Success</measure>
    <time_frame>Index-procedure</time_frame>
    <description>Device success is defined as successful delivery, balloon inflation and deflation and retrieval of the intact study device without burst below the rated burst pressure (RBP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Clinical Success</measure>
    <time_frame>prior to discharge</time_frame>
    <description>Clinical success is defined as procedural success without procedural complications (mortality, major target limb amputation, thrombosis of the target lesion, or TVR) prior to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - MAEs</measure>
    <time_frame>60 months</time_frame>
    <description>MAE (Major Adverse Events) is defined as all-cause mortality, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Clinically-driven TLR</measure>
    <time_frame>60 months</time_frame>
    <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - TVR</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - TLR</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Time to First Clinically-driven TLR (Days)</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - MAEs</measure>
    <time_frame>30 days</time_frame>
    <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - MAEs</measure>
    <time_frame>6 Months</time_frame>
    <description>MAE is defined as all-cause mortality, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - MAEs</measure>
    <time_frame>24 Months</time_frame>
    <description>MAE is defined as all-cause mortality, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - MAEs</measure>
    <time_frame>36 Months</time_frame>
    <description>MAE is defined as all-cause mortality, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - MAEs</measure>
    <time_frame>48 Months</time_frame>
    <description>MAE is defined as all-cause mortality, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Clinically-driven TLR</measure>
    <time_frame>30 days</time_frame>
    <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Clinically-driven TLR</measure>
    <time_frame>6 Months</time_frame>
    <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Clinically-driven TLR</measure>
    <time_frame>24 Months</time_frame>
    <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Clinically-driven TLR</measure>
    <time_frame>36 Months</time_frame>
    <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Clinically-driven TLR</measure>
    <time_frame>48 Months</time_frame>
    <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - TLR</measure>
    <time_frame>6 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - TLR</measure>
    <time_frame>24 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - TLR</measure>
    <time_frame>36 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - TLR</measure>
    <time_frame>48 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - TVR</measure>
    <time_frame>24 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - TVR</measure>
    <time_frame>36 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - TVR</measure>
    <time_frame>48 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - TVR</measure>
    <time_frame>6 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Time to All-cause Mortality Through 60 Months Post-index Procedure.</measure>
    <time_frame>60 months</time_frame>
    <description>All-cause mortality is reported by using the survival estimate of all cause mortality through 60 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Primary Sustained Clinical Improvement</measure>
    <time_frame>6 Months</time_frame>
    <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Primary Sustained Clinical Improvement</measure>
    <time_frame>12 Months</time_frame>
    <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Primary Sustained Clinical Improvement</measure>
    <time_frame>24 Months</time_frame>
    <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Primary Sustained Clinical Improvement</measure>
    <time_frame>36 Months</time_frame>
    <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Secondary Sustained Clinical Improvement</measure>
    <time_frame>6 Months</time_frame>
    <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Secondary Sustained Clinical Improvement</measure>
    <time_frame>12 Months</time_frame>
    <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Secondary Sustained Clinical Improvement</measure>
    <time_frame>24 Months</time_frame>
    <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Secondary Sustained Clinical Improvement</measure>
    <time_frame>36 Months</time_frame>
    <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Immediate Hemodynamic Improvement at Post-index Procedure</measure>
    <time_frame>Post procedure</time_frame>
    <description>Immediate hemodynamic improvement is defined as an ABI improvement of ≥ 0.1 or to an ABI ≥ 0.9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Sustained Hemodynamic Improvement</measure>
    <time_frame>6 Months</time_frame>
    <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Sustained Hemodynamic Improvement</measure>
    <time_frame>12 Months</time_frame>
    <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Sustained Hemodynamic Improvement</measure>
    <time_frame>24 Months</time_frame>
    <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Sustained Hemodynamic Improvement</measure>
    <time_frame>36 Months</time_frame>
    <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Health Related Quality of Life Scores (EQ5D Index)</measure>
    <time_frame>6 Months</time_frame>
    <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Health Related Quality of Life Scores (EQ5D Index)</measure>
    <time_frame>12 Months</time_frame>
    <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Health Related Quality of Life Scores (EQ5D Index)</measure>
    <time_frame>24 Months</time_frame>
    <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Health Related Quality of Life Scores (EQ5D Index)</measure>
    <time_frame>36 Months</time_frame>
    <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Procedural Success</measure>
    <time_frame>at procedure</time_frame>
    <description>Procedural Success is defined as residual stenosis of ≤ 50% (non-stented subjects) or ≤ 30% (stented subjects) by visual estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging Cohort ITT - Duplex-defined Binary Restenosis (PSVR &gt; 2.0) of the Target Lesion</measure>
    <time_frame>at 12 months, or at the time of re-intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging Cohort ITT - Duplex-defined Binary Restenosis (PSVR &gt; 3.4) of the Target Lesion</measure>
    <time_frame>At 12 months, or at the time of re-intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - MAEs</measure>
    <time_frame>30 days</time_frame>
    <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - MAEs</measure>
    <time_frame>6 months</time_frame>
    <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - MAEs</measure>
    <time_frame>12 months</time_frame>
    <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - MAEs</measure>
    <time_frame>24 months</time_frame>
    <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - MAEs</measure>
    <time_frame>36 months</time_frame>
    <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 36 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - MAEs</measure>
    <time_frame>48 months</time_frame>
    <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 48 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - MAEs</measure>
    <time_frame>60 months</time_frame>
    <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 60 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Clinically-driven TLR</measure>
    <time_frame>30 days</time_frame>
    <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Clinically-driven TLR</measure>
    <time_frame>6 months</time_frame>
    <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Clinically-driven TLR</measure>
    <time_frame>24 months</time_frame>
    <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Clinically-driven TLR</measure>
    <time_frame>36 months</time_frame>
    <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Clinically-driven TLR</measure>
    <time_frame>48 months</time_frame>
    <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Clinically-driven TLR</measure>
    <time_frame>60 months</time_frame>
    <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - TLR</measure>
    <time_frame>6 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - TLR</measure>
    <time_frame>12 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - TLR</measure>
    <time_frame>24 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - TLR</measure>
    <time_frame>36 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - TLR</measure>
    <time_frame>48 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - TLR</measure>
    <time_frame>60 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - TVR</measure>
    <time_frame>6 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - TVR</measure>
    <time_frame>12 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - TVR</measure>
    <time_frame>24 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - TVR</measure>
    <time_frame>36 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - TVR</measure>
    <time_frame>48 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - TVR</measure>
    <time_frame>60 Months</time_frame>
    <description>Any Target lesion revascularisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Time to First Clinically-driven TLR (Days)</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Time to All-cause Mortality Through 60 Months Post-index Procedure.</measure>
    <time_frame>60 months</time_frame>
    <description>All-cause mortality is reported by using the survival estimate of all-cause mortality through 60 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Primary Sustained Clinical Improvement</measure>
    <time_frame>6 months.</time_frame>
    <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Primary Sustained Clinical Improvement</measure>
    <time_frame>12 months.</time_frame>
    <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Primary Sustained Clinical Improvement</measure>
    <time_frame>24 months</time_frame>
    <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Primary Sustained Clinical Improvement</measure>
    <time_frame>36 months</time_frame>
    <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Secondary Sustained Clinical Improvement</measure>
    <time_frame>6 Months</time_frame>
    <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Secondary Sustained Clinical Improvement</measure>
    <time_frame>12 Months</time_frame>
    <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Secondary Sustained Clinical Improvement</measure>
    <time_frame>24 Months</time_frame>
    <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Secondary Sustained Clinical Improvement</measure>
    <time_frame>36 Months</time_frame>
    <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Immediate Hemodynamic Improvement at Post-index Procedure</measure>
    <time_frame>Post procedure</time_frame>
    <description>Immediate hemodynamic improvement is defined as an ABI improvement of ≥ 0.1 or to an ABI ≥ 0.9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Sustained Hemodynamic Improvement</measure>
    <time_frame>6 Months</time_frame>
    <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Sustained Hemodynamic Improvement</measure>
    <time_frame>12 Months</time_frame>
    <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Sustained Hemodynamic Improvement</measure>
    <time_frame>24 Months</time_frame>
    <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Sustained Hemodynamic Improvement</measure>
    <time_frame>36 Months</time_frame>
    <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Health Related Quality of Life Scores (EQ5D Index)</measure>
    <time_frame>6 Months</time_frame>
    <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Health Related Quality of Life Scores (EQ5D Index)</measure>
    <time_frame>12 Months</time_frame>
    <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Health Related Quality of Life Scores (EQ5D Index)</measure>
    <time_frame>24 Months</time_frame>
    <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Health Related Quality of Life Scores (EQ5D Index)</measure>
    <time_frame>36 Months</time_frame>
    <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Device Success</measure>
    <time_frame>Index-procedure</time_frame>
    <description>Device success is defined as successful delivery, balloon inflation and deflation and retrieval of the intact study device without burst below the rated burst pressure (RBP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Procedural Success</measure>
    <time_frame>at procedure</time_frame>
    <description>Procedural Success is defined as residual stenosis of ≤ 50% (non-stented subjects) or ≤ 30% (stented subjects) by visual estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Clinical Success</measure>
    <time_frame>prior to discharge</time_frame>
    <description>Clinical success is defined as procedural success without procedural complications (mortality, major target limb amputation, thrombosis of the target lesion, or TVR) prior to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - All-cause Mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - All-cause Mortality</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - All-cause Mortality</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - All-cause Mortality</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - All-cause Mortality</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - All-cause Mortality</measure>
    <time_frame>48 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - All-cause Mortality</measure>
    <time_frame>60 Months</time_frame>
    <description>The difference in death count calculation between the compliance table (participant flow: 253 deaths) and the event table (244 deaths) is explained as follow:&#xD;
Calendar days (365/year) is used for compliance table whereas 360-day annual cutoff is used for event rate calculation&#xD;
Compliance table used visit window as specified by protocol (60 days for 5-year follow-up) whereas, not window is used for event rate calculation&#xD;
Nine patients died between 1801 and 1885 (1825 + 60) and were therefore not included in the 5-year death rate summary but were included in the compliance summary for patients that died through the upper window of the 60 month visit.&#xD;
The denominator of 1215 for 1800-day event rate includes those who had an event within 1800 days and those who did not have any event but had at least 1740 days of follow-up (1740 is the low bound of the 60-day visit window from the target day of 1800)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Clinically-driven TVR</measure>
    <time_frame>30 days</time_frame>
    <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Clinically-driven TVR</measure>
    <time_frame>6 Months</time_frame>
    <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Clinically-driven TVR</measure>
    <time_frame>12 Months</time_frame>
    <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Clinical Cohort ITT - Clinically-driven TVR</measure>
    <time_frame>24 Months</time_frame>
    <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Clinically-driven TVR</measure>
    <time_frame>36 Months</time_frame>
    <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Clinically-driven TVR</measure>
    <time_frame>48 Months</time_frame>
    <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Clinically-driven TVR</measure>
    <time_frame>60 Months</time_frame>
    <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Major Target Limb Amputation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Major Target Limb Amputation</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Major Target Limb Amputation</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Major Target Limb Amputation</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Major Target Limb Amputation</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Major Target Limb Amputation</measure>
    <time_frame>48 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cohort ITT - Major Target Limb Amputation</measure>
    <time_frame>60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - All-cause Mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - All-cause Mortality</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - All-cause Mortality</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - All-cause Mortality</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - All-cause Mortality</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - All-cause Mortality</measure>
    <time_frame>48 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - All-cause Mortality</measure>
    <time_frame>60 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Clinically-driven TVR</measure>
    <time_frame>30 days</time_frame>
    <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Clinically-driven TVR</measure>
    <time_frame>6 Months</time_frame>
    <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Clinically-driven TVR</measure>
    <time_frame>12 Months</time_frame>
    <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Clinically-driven TVR</measure>
    <time_frame>24 Months</time_frame>
    <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Clinically-driven TVR</measure>
    <time_frame>36 Months</time_frame>
    <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Clinically-driven TVR</measure>
    <time_frame>48 Months</time_frame>
    <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Clinically-driven TVR</measure>
    <time_frame>60 Months</time_frame>
    <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Major Target Limb Amputation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Major Target Limb Amputation</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Major Target Limb Amputation</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Major Target Limb Amputation</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Major Target Limb Amputation</measure>
    <time_frame>36 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Major Target Limb Amputation</measure>
    <time_frame>48 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>150mm DEB ITT Cohort - Major Target Limb Amputation</measure>
    <time_frame>60 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1535</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>IN.PACT Admiral DEB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects in this trial will be treated with the IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon (hereinafter referred as &quot;IN.PACT Admiral™ DEB&quot;)manufactured by Medtronic. The IN.PACT Admiral™ is a CE (Conformité Europeénne, European Confirmity) marked medical device utilized within its intended use in the IN.PACT Global trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IN.PACT Admiral™ Drug Eluting Balloon</intervention_name>
    <description>IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon.</description>
    <arm_group_label>IN.PACT Admiral DEB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years or minimum age as required by local regulations.&#xD;
&#xD;
          -  Subject with documented diagnosis of peripheral arterial disease (PAD) in the&#xD;
             superficial femoral artery (SFA) and/or popliteal artery (PA) (including P1, P2, P3)&#xD;
             classified as Rutherford class 2-3-4.&#xD;
&#xD;
          -  Angiographically documented single or multiple lesions/occlusions (de novo or&#xD;
             re-stenotic lesion(s) or in-stent restenosis) within the target vessels with a minimum&#xD;
             lesion length of 2 cm including bilateral disease if both limbs are treated within 35&#xD;
             days.&#xD;
&#xD;
        General exclusion Criteria:&#xD;
&#xD;
          -  High probability of non-adherence to Clinical Investigation Protocol follow-up&#xD;
             requirements.&#xD;
&#xD;
          -  Failure to successfully cross the target lesion with a guide wire (successful crossing&#xD;
             means tip of the guide wire distal to the target lesion in the absence of flow&#xD;
             limiting dissections or perforations).&#xD;
&#xD;
          -  Lesion within or adjacent to an aneurysm or presence of a popliteal aneurysm.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar Tepe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Rosenheim</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary Ansel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MidOhio Cardiology and Vascular Consultants</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Bosiers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ Sint Blasius</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Do-Dai Do, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swiss Cardiovascular Center, Inselspital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Gaines, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheffield Vascular Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alvaro Razuk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Ciências Médicas da Santa Casa de Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundación Favaloro</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica La Sagrada Familia</name>
      <address>
        <city>Bueos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <zip>NSW 2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landesklinikum Thermenregion Mödling</name>
      <address>
        <city>Mödling</city>
        <zip>2340</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze-Lieve-Vrouwziekenuis</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda Ziekenhuis</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St. Blasius</name>
      <address>
        <city>Dendermonde</city>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost Limburg - Campus St.-Jan</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionaal Ziekenhuis Heilig Hart</name>
      <address>
        <city>Tienen</city>
        <zip>3300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire Sherbrooke (CHUS)</name>
      <address>
        <city>Sherbrooke</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Santa Maria</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Medilaser Neiva</name>
      <address>
        <city>Neiva</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>As-Salam International Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Egypt Air Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsingin Seudun Yliopistollinen Keskussairaala</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Group Hospitalier Pellegrin - CHU</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Les Hospitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta-Krankenhaus</name>
      <address>
        <city>Duesseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta Krankenhaus</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40472</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig AoR</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park-Krankenhaus Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Franziskus Hospital GmbH</name>
      <address>
        <city>Münster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RoMed Klinikum Rosenheim</name>
      <address>
        <city>Rosenheim</city>
        <zip>83022</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Patras</name>
      <address>
        <city>Patra</city>
        <zip>TK26504</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bacs Kiskun Megyei Korhaz</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Centre</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center - Beilison Hospital</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Eleonora Hospital</name>
      <address>
        <city>Palermo</city>
        <zip>90135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Gemelli</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severence Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>443-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaunas Mecial University Clinic</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>'s Hertogenbosch</city>
        <zip>5223GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Ziekenhuis</name>
      <address>
        <city>Arnhem</city>
        <zip>6800TA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3430EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Euromedic Medical Center</name>
      <address>
        <city>Katowice</city>
        <zip>40-519</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 2</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Marta</name>
      <address>
        <city>Lisbon</city>
        <zip>1169-024</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital named after M.E. Zhadkevich</name>
      <address>
        <city>Moscow</city>
        <zip>121374</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stredoslovensky ustav srdcovych a cievnych chorob (SUSCCH)</name>
      <address>
        <city>Banská Bystrica</city>
        <zip>97401</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Národný ústav srdcových a cievnych chorôb a.s. (NUSCH)</name>
      <address>
        <city>Bratislava</city>
        <zip>83348</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Východoslovenský ústav srdcových a cievnych chorôb, a.s.(VUSH)</name>
      <address>
        <city>Kosice</city>
        <zip>04011</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Maribor</name>
      <address>
        <city>Maribor</city>
        <zip>2000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset</name>
      <address>
        <city>Solna</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital - Universitätsspial Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal HFR</name>
      <address>
        <city>Fribourg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonspital Luzern</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M139WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern General Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S57AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Egypt</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 24, 2012</study_first_submitted>
  <study_first_submitted_qc>May 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2012</study_first_posted>
  <results_first_submitted>May 4, 2017</results_first_submitted>
  <results_first_submitted_qc>August 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 28, 2019</results_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Arterial Disease</keyword>
  <keyword>Drug coated balloon</keyword>
  <keyword>Superficial Femoral Artery</keyword>
  <keyword>Popliteal Femoral Artery</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Drug eluting balloon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Clinical Cohort ITT</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1406"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="918"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="488"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="253"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Exit reason other than withdrawal, death or lost to follow up</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>missed visit but known to be alive</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clinical Cohort ITT</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1406"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Due to missing data number analyzed for age differs from overall number of participants</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1396"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.6" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1406"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="453"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Cohort ITT - Primary Effectiveness Endpoint</title>
        <description>Freedom from clinically-driven target lesion revascularization (TLR) within 12 months post-index procedure, which is defined as: • Any re-intervention within the target lesion(s) due to symptoms or drop of ABI ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Primary Effectiveness Endpoint</title>
          <description>Freedom from clinically-driven target lesion revascularization (TLR) within 12 months post-index procedure, which is defined as: • Any re-intervention within the target lesion(s) due to symptoms or drop of ABI ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Cohort ITT - Primary Safety Endpoint</title>
        <description>A composite of freedom from device- and procedure-related mortality through 30 days, freedom from major target limb amputation and TLR within 12 months post-index procedure.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Primary Safety Endpoint</title>
          <description>A composite of freedom from device- and procedure-related mortality through 30 days, freedom from major target limb amputation and TLR within 12 months post-index procedure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Imaging Cohort ITT - Primary Effectiveness Endpoint</title>
        <description>Primary Patency within 12 months post-index procedure, which is defined as:&#xD;
Freedom from clinically-driven TLR and&#xD;
Freedom from restenosis as determined by DUS Peak Systolic Velocity Ratio (PSVR) ≤ 2.4.&#xD;
Restenosis determined by either PSVR &gt;2.4 as assessed by an independent DUS core lab or &gt;50% stenosis as assessed by an independent angiographic core lab.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imaging Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Imaging Cohort ITT - Primary Effectiveness Endpoint</title>
          <description>Primary Patency within 12 months post-index procedure, which is defined as:&#xD;
Freedom from clinically-driven TLR and&#xD;
Freedom from restenosis as determined by DUS Peak Systolic Velocity Ratio (PSVR) ≤ 2.4.&#xD;
Restenosis determined by either PSVR &gt;2.4 as assessed by an independent DUS core lab or &gt;50% stenosis as assessed by an independent angiographic core lab.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>150mm DEB ITT Cohort - Primary Effectiveness Endpoint</title>
        <description>Freedom from clinically-driven target lesion revascularization (TLR) within 12 months post-index procedure, which is defined as:&#xD;
• Any re-intervention within the target lesion(s) due to symptoms or drop of ABI ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Primary Effectiveness Endpoint</title>
          <description>Freedom from clinically-driven target lesion revascularization (TLR) within 12 months post-index procedure, which is defined as:&#xD;
• Any re-intervention within the target lesion(s) due to symptoms or drop of ABI ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - MAEs</title>
        <description>MAE (Major Adverse Events) is defined as all-cause mortality, clinically-driven TVR (Target Vessel Revascularization), major target limb amputation, thrombosis at the target lesion site.</description>
        <time_frame>12 months</time_frame>
        <population>Event rates are based on number of evaluable subjects - subjects with at least one MAE event within 360-day or subjects without any MAE event but had at least 300 days of clinical follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - MAEs</title>
          <description>MAE (Major Adverse Events) is defined as all-cause mortality, clinically-driven TVR (Target Vessel Revascularization), major target limb amputation, thrombosis at the target lesion site.</description>
          <population>Event rates are based on number of evaluable subjects - subjects with at least one MAE event within 360-day or subjects without any MAE event but had at least 300 days of clinical follow-up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All MAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All cause death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD-TVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Target Limb Amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis at Target Lesion Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - TLR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - TLR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - TVR</title>
        <description>Any Target vessel revascularisation</description>
        <time_frame>12 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - TVR</title>
          <description>Any Target vessel revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Device Success</title>
        <description>Device success is defined as successful delivery, balloon inflation and deflation and retrieval of the intact study device without burst below the rated burst pressure (RBP)</description>
        <time_frame>Index-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Device Success</title>
          <description>Device success is defined as successful delivery, balloon inflation and deflation and retrieval of the intact study device without burst below the rated burst pressure (RBP)</description>
          <units>Admiral™ Drug-Eluting Balloon</units>
          <param>Count of Units</param>
          <units_analyzed>Admiral™ Drug-Eluting Balloon</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1406"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Admiral™ Drug-Eluting Balloon</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2988"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Clinical Success</title>
        <description>Clinical success is defined as procedural success without procedural complications (mortality, major target limb amputation, thrombosis of the target lesion, or TVR) prior to discharge</description>
        <time_frame>prior to discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Clinical Success</title>
          <description>Clinical success is defined as procedural success without procedural complications (mortality, major target limb amputation, thrombosis of the target lesion, or TVR) prior to discharge</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - MAEs</title>
        <description>MAE (Major Adverse Events) is defined as all-cause mortality, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site.</description>
        <time_frame>60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
            <description>Death, Major Target Limb Amputation, Clinically-driven TVR, Thrombosis</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - MAEs</title>
          <description>MAE (Major Adverse Events) is defined as all-cause mortality, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD-TVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Target Limb Amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis At Target Lesion Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Clinically-driven TLR</title>
        <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Clinically-driven TLR</title>
          <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - TVR</title>
        <time_frame>60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - TVR</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - TLR</title>
        <time_frame>60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - TLR</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Time to First Clinically-driven TLR (Days)</title>
        <time_frame>60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Time to First Clinically-driven TLR (Days)</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="669.2" spread="462.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - MAEs</title>
        <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 30 days.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - MAEs</title>
          <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 30 days.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD-TVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Target Limb Amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis at Target Lesion Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - MAEs</title>
        <description>MAE is defined as all-cause mortality, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - MAEs</title>
          <description>MAE is defined as all-cause mortality, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD-TVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Target Limb Amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis at Target Lesion Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - MAEs</title>
        <description>MAE is defined as all-cause mortality, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site.</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - MAEs</title>
          <description>MAE is defined as all-cause mortality, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD-TVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Target Limb Amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis at Target Lesion Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - MAEs</title>
        <description>MAE is defined as all-cause mortality, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site.</description>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - MAEs</title>
          <description>MAE is defined as all-cause mortality, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All cause deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD-TVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Target Limb Amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis at Target Lesion Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - MAEs</title>
        <description>MAE is defined as all-cause mortality, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site.</description>
        <time_frame>48 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - MAEs</title>
          <description>MAE is defined as all-cause mortality, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All cause deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD-TVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Target Limb Amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis at Target Lesion Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Clinically-driven TLR</title>
        <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Clinically-driven TLR</title>
          <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Clinically-driven TLR</title>
        <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Clinically-driven TLR</title>
          <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Clinically-driven TLR</title>
        <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Clinically-driven TLR</title>
          <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Clinically-driven TLR</title>
        <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Clinically-driven TLR</title>
          <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Clinically-driven TLR</title>
        <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>48 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Clinically-driven TLR</title>
          <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - TLR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - TLR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - TLR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - TLR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - TLR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - TLR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - TLR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>48 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - TLR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - TVR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - TVR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - TVR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - TVR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - TVR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>48 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - TVR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - TVR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - TVR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Time to All-cause Mortality Through 60 Months Post-index Procedure.</title>
        <description>All-cause mortality is reported by using the survival estimate of all cause mortality through 60 months</description>
        <time_frame>60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Time to All-cause Mortality Through 60 Months Post-index Procedure.</title>
          <description>All-cause mortality is reported by using the survival estimate of all cause mortality through 60 months</description>
          <units>percentage of survival</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1406"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.5" lower_limit="78.2" upper_limit="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Primary Sustained Clinical Improvement</title>
        <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Primary Sustained Clinical Improvement</title>
          <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Primary Sustained Clinical Improvement</title>
        <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects</description>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Primary Sustained Clinical Improvement</title>
          <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Primary Sustained Clinical Improvement</title>
        <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Primary Sustained Clinical Improvement</title>
          <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1073"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Primary Sustained Clinical Improvement</title>
        <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects</description>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Primary Sustained Clinical Improvement</title>
          <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1009"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Secondary Sustained Clinical Improvement</title>
        <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Secondary Sustained Clinical Improvement</title>
          <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Secondary Sustained Clinical Improvement</title>
        <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Secondary Sustained Clinical Improvement</title>
          <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Secondary Sustained Clinical Improvement</title>
        <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Secondary Sustained Clinical Improvement</title>
          <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1033"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Secondary Sustained Clinical Improvement</title>
        <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Secondary Sustained Clinical Improvement</title>
          <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Immediate Hemodynamic Improvement at Post-index Procedure</title>
        <description>Immediate hemodynamic improvement is defined as an ABI improvement of ≥ 0.1 or to an ABI ≥ 0.9</description>
        <time_frame>Post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Immediate Hemodynamic Improvement at Post-index Procedure</title>
          <description>Immediate hemodynamic improvement is defined as an ABI improvement of ≥ 0.1 or to an ABI ≥ 0.9</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Sustained Hemodynamic Improvement</title>
        <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Sustained Hemodynamic Improvement</title>
          <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Sustained Hemodynamic Improvement</title>
        <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Sustained Hemodynamic Improvement</title>
          <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1088"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Sustained Hemodynamic Improvement</title>
        <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Sustained Hemodynamic Improvement</title>
          <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Sustained Hemodynamic Improvement</title>
        <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Sustained Hemodynamic Improvement</title>
          <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="900"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="437"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</title>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</title>
          <units>percentage of impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.7" spread="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</title>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</title>
          <units>percentage of impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</title>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</title>
          <units>percentage of impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="952"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</title>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</title>
          <units>percentage of impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="831"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" spread="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Health Related Quality of Life Scores (EQ5D Index)</title>
        <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Health Related Quality of Life Scores (EQ5D Index)</title>
          <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8124" spread="0.2323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Health Related Quality of Life Scores (EQ5D Index)</title>
        <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Health Related Quality of Life Scores (EQ5D Index)</title>
          <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7970" spread="0.2413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Health Related Quality of Life Scores (EQ5D Index)</title>
        <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Health Related Quality of Life Scores (EQ5D Index)</title>
          <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="964"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7744" spread="0.2551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Health Related Quality of Life Scores (EQ5D Index)</title>
        <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Health Related Quality of Life Scores (EQ5D Index)</title>
          <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="837"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7629" spread="0.2641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Procedural Success</title>
        <description>Procedural Success is defined as residual stenosis of ≤ 50% (non-stented subjects) or ≤ 30% (stented subjects) by visual estimate</description>
        <time_frame>at procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Procedural Success</title>
          <description>Procedural Success is defined as residual stenosis of ≤ 50% (non-stented subjects) or ≤ 30% (stented subjects) by visual estimate</description>
          <units>lesions</units>
          <param>Count of Units</param>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1406"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1761"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Imaging Cohort ITT - Duplex-defined Binary Restenosis (PSVR &gt; 2.0) of the Target Lesion</title>
        <time_frame>at 12 months, or at the time of re-intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imaging Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Imaging Cohort ITT - Duplex-defined Binary Restenosis (PSVR &gt; 2.0) of the Target Lesion</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Imaging Cohort ITT - Duplex-defined Binary Restenosis (PSVR &gt; 3.4) of the Target Lesion</title>
        <time_frame>At 12 months, or at the time of re-intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imaging Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Imaging Cohort ITT - Duplex-defined Binary Restenosis (PSVR &gt; 3.4) of the Target Lesion</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - MAEs</title>
        <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 30 days.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - MAEs</title>
          <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 30 days.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD-TVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Target Limb Amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis at Target Lesion Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - MAEs</title>
        <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 6 months.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - MAEs</title>
          <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 6 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD-TVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Target Limb Amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis at Target Lesion Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - MAEs</title>
        <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 12 months.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - MAEs</title>
          <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 12 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD-TVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Target Limb Amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis at Target Lesion Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - MAEs</title>
        <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 24 months.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - MAEs</title>
          <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 24 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD-TVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Target Limb Amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis at Target Lesion Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - MAEs</title>
        <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 36 months.</description>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - MAEs</title>
          <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 36 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD-TVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Target Limb Amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis at Target Lesion Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - MAEs</title>
        <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 48 months.</description>
        <time_frame>48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - MAEs</title>
          <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 48 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD-TVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Target Limb Amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis at Target Lesion Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - MAEs</title>
        <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 60 months.</description>
        <time_frame>60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - MAEs</title>
          <description>Major Adverse Events (MAE) defined as all-cause death, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site at 60 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD-TVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Target Limb Amputation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis at Target Lesion Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Clinically-driven TLR</title>
        <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Clinically-driven TLR</title>
          <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Clinically-driven TLR</title>
        <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Clinically-driven TLR</title>
          <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Clinically-driven TLR</title>
        <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Clinically-driven TLR</title>
          <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Clinically-driven TLR</title>
        <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Clinically-driven TLR</title>
          <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Clinically-driven TLR</title>
        <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Clinically-driven TLR</title>
          <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Clinically-driven TLR</title>
        <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Clinically-driven TLR</title>
          <description>Clinically-driven TLR is defined as any re-intervention at the target lesion due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - TLR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - TLR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - TLR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - TLR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - TLR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - TLR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - TLR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - TLR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - TLR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>48 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - TLR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - TLR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>60 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - TLR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - TVR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - TVR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - TVR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - TVR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - TVR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - TVR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - TVR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - TVR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - TVR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>48 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - TVR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - TVR</title>
        <description>Any Target lesion revascularisation</description>
        <time_frame>60 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - TVR</title>
          <description>Any Target lesion revascularisation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Time to First Clinically-driven TLR (Days)</title>
        <time_frame>60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Time to First Clinically-driven TLR (Days)</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="622.2" spread="352.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Time to All-cause Mortality Through 60 Months Post-index Procedure.</title>
        <description>All-cause mortality is reported by using the survival estimate of all-cause mortality through 60 months</description>
        <time_frame>60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Time to All-cause Mortality Through 60 Months Post-index Procedure.</title>
          <description>All-cause mortality is reported by using the survival estimate of all-cause mortality through 60 months</description>
          <units>percentage of survival</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1" lower_limit="72.2" upper_limit="87.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Primary Sustained Clinical Improvement</title>
        <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>6 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Primary Sustained Clinical Improvement</title>
          <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Primary Sustained Clinical Improvement</title>
        <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>12 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Primary Sustained Clinical Improvement</title>
          <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Primary Sustained Clinical Improvement</title>
        <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Primary Sustained Clinical Improvement</title>
          <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Primary Sustained Clinical Improvement</title>
        <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Primary Sustained Clinical Improvement</title>
          <description>Primary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Secondary Sustained Clinical Improvement</title>
        <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150 mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Secondary Sustained Clinical Improvement</title>
          <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Secondary Sustained Clinical Improvement</title>
        <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Secondary Sustained Clinical Improvement</title>
          <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Secondary Sustained Clinical Improvement</title>
        <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Secondary Sustained Clinical Improvement</title>
          <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Secondary Sustained Clinical Improvement</title>
        <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Secondary Sustained Clinical Improvement</title>
          <description>Secondary sustained clinical improvement is defined as sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Immediate Hemodynamic Improvement at Post-index Procedure</title>
        <description>Immediate hemodynamic improvement is defined as an ABI improvement of ≥ 0.1 or to an ABI ≥ 0.9</description>
        <time_frame>Post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Immediate Hemodynamic Improvement at Post-index Procedure</title>
          <description>Immediate hemodynamic improvement is defined as an ABI improvement of ≥ 0.1 or to an ABI ≥ 0.9</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Sustained Hemodynamic Improvement</title>
        <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Sustained Hemodynamic Improvement</title>
          <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Sustained Hemodynamic Improvement</title>
        <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Sustained Hemodynamic Improvement</title>
          <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Sustained Hemodynamic Improvement</title>
        <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Sustained Hemodynamic Improvement</title>
          <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Sustained Hemodynamic Improvement</title>
        <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Sustained Hemodynamic Improvement</title>
          <description>Sustained hemodynamic improvement is defined as persistent improvement of ABI- values with ≥ 0.1 as compared to baseline values or to an ABI ≥ 0.9 throughout follow-up without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</title>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</title>
          <units>percentage of impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.9" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</title>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</title>
          <units>percentage of impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5" spread="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</title>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</title>
          <units>percentage of impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4" spread="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</title>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Walking Impairment Evaluation by Walking Impairment Questionnaire (WIQ)</title>
          <units>percentage of impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Health Related Quality of Life Scores (EQ5D Index)</title>
        <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Health Related Quality of Life Scores (EQ5D Index)</title>
          <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8463" spread="0.1771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Health Related Quality of Life Scores (EQ5D Index)</title>
        <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Health Related Quality of Life Scores (EQ5D Index)</title>
          <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8257" spread="0.1853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Health Related Quality of Life Scores (EQ5D Index)</title>
        <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Health Related Quality of Life Scores (EQ5D Index)</title>
          <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7858" spread="0.2215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Health Related Quality of Life Scores (EQ5D Index)</title>
        <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Health Related Quality of Life Scores (EQ5D Index)</title>
          <description>The total EQ-5D-3L UK Index Score was computed using the algorithm specified by the EuroQol Research Foundation with possible values ranging from -0.594 to 1 where higher values are better.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8278" spread="0.2003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Device Success</title>
        <description>Device success is defined as successful delivery, balloon inflation and deflation and retrieval of the intact study device without burst below the rated burst pressure (RBP)</description>
        <time_frame>Index-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Device Success</title>
          <description>Device success is defined as successful delivery, balloon inflation and deflation and retrieval of the intact study device without burst below the rated burst pressure (RBP)</description>
          <units>Admiral™ Drug-Eluting Balloon</units>
          <param>Count of Units</param>
          <units_analyzed>Admiral™ Drug-Eluting Balloon</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Admiral™ Drug-Eluting Balloon</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Procedural Success</title>
        <description>Procedural Success is defined as residual stenosis of ≤ 50% (non-stented subjects) or ≤ 30% (stented subjects) by visual estimate</description>
        <time_frame>at procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Procedural Success</title>
          <description>Procedural Success is defined as residual stenosis of ≤ 50% (non-stented subjects) or ≤ 30% (stented subjects) by visual estimate</description>
          <units>lesions</units>
          <param>Count of Units</param>
          <units_analyzed>lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Clinical Success</title>
        <description>Clinical success is defined as procedural success without procedural complications (mortality, major target limb amputation, thrombosis of the target lesion, or TVR) prior to discharge</description>
        <time_frame>prior to discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Clinical Success</title>
          <description>Clinical success is defined as procedural success without procedural complications (mortality, major target limb amputation, thrombosis of the target lesion, or TVR) prior to discharge</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - All-cause Mortality</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - All-cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - All-cause Mortality</title>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - All-cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - All-cause Mortality</title>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - All-cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - All-cause Mortality</title>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - All-cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - All-cause Mortality</title>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - All-cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - All-cause Mortality</title>
        <time_frame>48 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - All-cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - All-cause Mortality</title>
        <description>The difference in death count calculation between the compliance table (participant flow: 253 deaths) and the event table (244 deaths) is explained as follow:&#xD;
Calendar days (365/year) is used for compliance table whereas 360-day annual cutoff is used for event rate calculation&#xD;
Compliance table used visit window as specified by protocol (60 days for 5-year follow-up) whereas, not window is used for event rate calculation&#xD;
Nine patients died between 1801 and 1885 (1825 + 60) and were therefore not included in the 5-year death rate summary but were included in the compliance summary for patients that died through the upper window of the 60 month visit.&#xD;
The denominator of 1215 for 1800-day event rate includes those who had an event within 1800 days and those who did not have any event but had at least 1740 days of follow-up (1740 is the low bound of the 60-day visit window from the target day of 1800)</description>
        <time_frame>60 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - All-cause Mortality</title>
          <description>The difference in death count calculation between the compliance table (participant flow: 253 deaths) and the event table (244 deaths) is explained as follow:&#xD;
Calendar days (365/year) is used for compliance table whereas 360-day annual cutoff is used for event rate calculation&#xD;
Compliance table used visit window as specified by protocol (60 days for 5-year follow-up) whereas, not window is used for event rate calculation&#xD;
Nine patients died between 1801 and 1885 (1825 + 60) and were therefore not included in the 5-year death rate summary but were included in the compliance summary for patients that died through the upper window of the 60 month visit.&#xD;
The denominator of 1215 for 1800-day event rate includes those who had an event within 1800 days and those who did not have any event but had at least 1740 days of follow-up (1740 is the low bound of the 60-day visit window from the target day of 1800)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Clinically-driven TVR</title>
        <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Clinically-driven TVR</title>
          <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Clinically-driven TVR</title>
        <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Clinically-driven TVR</title>
          <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Clinically-driven TVR</title>
        <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Clinically-driven TVR</title>
          <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Clinical Cohort ITT - Clinically-driven TVR</title>
        <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Clinical Cohort ITT - Clinically-driven TVR</title>
          <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Clinically-driven TVR</title>
        <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Clinically-driven TVR</title>
          <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Clinically-driven TVR</title>
        <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>48 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Clinically-driven TVR</title>
          <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Clinically-driven TVR</title>
        <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>60 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Clinically-driven TVR</title>
          <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Major Target Limb Amputation</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Major Target Limb Amputation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Major Target Limb Amputation</title>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Major Target Limb Amputation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Major Target Limb Amputation</title>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Major Target Limb Amputation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1361"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Major Target Limb Amputation</title>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Major Target Limb Amputation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1313"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Major Target Limb Amputation</title>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Major Target Limb Amputation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Major Target Limb Amputation</title>
        <time_frame>48 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Major Target Limb Amputation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cohort ITT - Major Target Limb Amputation</title>
        <time_frame>60 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clinical Cohort ITT</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cohort ITT - Major Target Limb Amputation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - All-cause Mortality</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - All-cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - All-cause Mortality</title>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - All-cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - All-cause Mortality</title>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - All-cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - All-cause Mortality</title>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - All-cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - All-cause Mortality</title>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - All-cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - All-cause Mortality</title>
        <time_frame>48 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - All-cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - All-cause Mortality</title>
        <time_frame>60 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - All-cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Clinically-driven TVR</title>
        <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Clinically-driven TVR</title>
          <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Clinically-driven TVR</title>
        <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Clinically-driven TVR</title>
          <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Clinically-driven TVR</title>
        <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Clinically-driven TVR</title>
          <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Clinically-driven TVR</title>
        <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Clinically-driven TVR</title>
          <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Clinically-driven TVR</title>
        <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Clinically-driven TVR</title>
          <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Clinically-driven TVR</title>
        <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>48 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Clinically-driven TVR</title>
          <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Clinically-driven TVR</title>
        <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
        <time_frame>60 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Clinically-driven TVR</title>
          <description>Clinically-driven TVR is defined as any re-intervention within the target vessel due to symptoms or drop of ABI of ≥ 20% or &gt; 0.15 when compared to post-index procedure baseline ABI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Major Target Limb Amputation</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Major Target Limb Amputation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Major Target Limb Amputation</title>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Major Target Limb Amputation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Major Target Limb Amputation</title>
        <time_frame>12 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Major Target Limb Amputation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Major Target Limb Amputation</title>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Major Target Limb Amputation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Major Target Limb Amputation</title>
        <time_frame>36 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Major Target Limb Amputation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Major Target Limb Amputation</title>
        <time_frame>48 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Major Target Limb Amputation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Major Target Limb Amputation</title>
        <time_frame>60 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Major Target Limb Amputation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>150mm DEB ITT Cohort - Time to First Clinically-driven TLR (Days)</title>
        <time_frame>60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>150mm DEB ITT Cohort</title>
          </group>
        </group_list>
        <measure>
          <title>150mm DEB ITT Cohort - Time to First Clinically-driven TLR (Days)</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="622.2" spread="352.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Clinical Cohort 60M</title>
          <description>Events through the entire 60 months follow-up period are included</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="253" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1074" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Anaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hypochromic Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy Mediastinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Nephrogenic Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Normochromic Normocytic Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="57" subjects_affected="52" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="37" subjects_affected="34" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Aortic Valve Incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Aortic Valve Stenosis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis Coronary Artery</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="34" subjects_affected="31" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Atrial Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Complete</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Second Degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Atrioventricular Dissociation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bundle Branch Block Left</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cardiac Disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="66" subjects_affected="53" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cardiac Tamponade</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cardiac Valve Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary Failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cardiovascular Insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Congestive Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="54" subjects_affected="51" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Coronary Artery Insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Coronary Artery Occlusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" events="32" subjects_affected="26" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Coronary Artery Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Diastolic Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Heart Valve Incompetence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hypertensive Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hypertensive Heart Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Intracardiac Thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Ischaemic Cardiomyopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Left Ventricular Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Left Ventricular Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Low Cardiac Output Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Mitral Valve Incompetence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Mitral Valve Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Myocardial Fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Rhythm Idioventricular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Stress Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Trifascicular Block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Ventricle Rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital Arterial Malformation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Angiodysplasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Tympanic Membrane Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vertigo Positional</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism Tertiary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis Fugax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Blindness Unilateral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="25" subjects_affected="18" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cataract Cortical</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Dacryostenosis Acquired</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Lens Dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Macular Degeneration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Retinal Artery Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Visual Impairment</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vitreous Adhesions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vitreous Haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Abdominal Symptom</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Abdominal Wall Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Acute Abdomen</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Anal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Anal Skin Tags</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Colitis Ischaemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Colitis Ulcerative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Colonic Polyp</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Dental Caries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Erosive Duodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Faecal Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Food Poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gastric Haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gastric Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gastritis Erosive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Intestinal Ischaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Intestinal Polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Intra-Abdominal Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Jejunal Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Large Intestine Perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Lumbar Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Malignant Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Mechanical Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Mesenteric Artery Stenosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Oesophageal Achalasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Oesophageal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Oesophageal Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Oesophageal Varices Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pancreatitis Chronic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Peptic Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Rectal Polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Reflux Oesophagitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Sigmoiditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Small Intestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Spigelian Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cardiac Death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="55" subjects_affected="55" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Device Breakage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Device Dislocation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Device Malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Device Occlusion</sub_title>
                <counts group_id="E1" events="49" subjects_affected="45" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Euthanasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Exercise Tolerance Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gait Disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hernia Obstructive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hyperplasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Impaired Healing</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Infusion Site Extravasation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Puncture Site Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Sudden Cardiac Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Thrombosis In Device</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Haematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Haemorrhage</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile Duct Stone</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cholangitis Acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gallbladder Necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hepatic Cirrhosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Liver Disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Appendicitis Perforated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bone Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Colitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Diabetic Gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Enterococcal Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Febrile Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Fungal Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Graft Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Groin Abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Groin Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Haematoma Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Helicobacter Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hepatic Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Herpes Zoster Infection Neurological</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Herpes Zoster Ophthalmic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Infected Lymphocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Infected Skin Ulcer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Infective Exacerbation Of Chronic Obstructive Airways Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Kidney Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Necrotising Fasciitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Osteomyelitis Chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Periorbital Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Peritoneal Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="85" subjects_affected="70" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Post Procedural Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Postoperative Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Prostatic Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pseudomembranous Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pulmonary Sepsis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Severe Acute Respiratory Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Staphylococcal Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Wound Infection Bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Wound Infection Staphylococcal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Wound Sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol Poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Anaemia Postoperative</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Anastomotic Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Arterial Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Arterial Restenosis</sub_title>
                <counts group_id="E1" events="204" subjects_affected="143" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Arteriovenous Fistula Site Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Arteriovenous Fistula Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cervical Vertebral Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Chemical Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Colon Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Coronary Artery Restenosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Drug Toxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Facial Bones Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Femoral Nerve Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Fibula Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Foreign Body</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Fractured Sacrum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Anastomotic Leak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>In-Stent Arterial Restenosis</sub_title>
                <counts group_id="E1" events="113" subjects_affected="87" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>In-Stent Coronary Artery Restenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Incisional Hernia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Meniscus Lesion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Multiple Fractures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Multiple Injuries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Nerve Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Patella Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pelvic Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Reocclusion</sub_title>
                <counts group_id="E1" events="52" subjects_affected="40" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Periprosthetic Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Post Laminectomy Syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Post Procedural Complication</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Post Procedural Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Post Procedural Haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Post Procedural Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Postoperative Thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Procedural Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pubis Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Radiation Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Shunt Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Shunt Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Skin Laceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Spinal Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Sternal Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Thermal Burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Thoracic Vertebral Fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Traumatic Brain Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Traumatic Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Ulna Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Urinary Retention Postoperative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vascular Graft Complication</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vascular Graft Occlusion</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vascular Graft Thrombosis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vascular Procedure Complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vascular Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="36" subjects_affected="33" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Venous Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Wound Complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Wound Decomposition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Wound Dehiscence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Wound Necrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram Coronary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Blood Glucose Abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Blood Glucose Fluctuation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Blood Sodium Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>C-Reactive Protein Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Chest X-Ray Abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Clostridium Test Positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>International Normalised Ratio Increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Investigation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Scan Abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Transplant Evaluation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Diabetic Foot</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Insulin Resistance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Metabolic Acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Metabolic Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Type 1 Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cervical Spinal Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Compartment Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Dupuytren's Contracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Foot Deformity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gouty Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Groin Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Meniscal Degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Nodule On Extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Polymyositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Rotator Cuff Syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Soft Tissue Necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Systemic Sclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Tendon Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Trigger Finger</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma Pancreas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Benign Lung Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Benign Renal Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Benign Spleen Tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bile Duct Cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bladder Cancer Recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bladder Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bladder Papilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bladder Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bladder Transitional Cell Carcinoma Recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bone Neoplasm Malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Brain Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Brain Neoplasm Malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Breast Cancer Metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bronchial Carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Carcinoid Tumour Of The Caecum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Carcinoma In Situ Of Skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Colon Adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Colon Neoplasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Colorectal Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Endometrial Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gastric Cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hepatic Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hepatic Neoplasm Malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Laryngeal Cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Laryngeal Cancer Recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Lentigo Maligna Stage Unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Lung Adenocarcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Lung Adenocarcinoma Stage I</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Lung Adenocarcinoma Stage Iii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Lung Cancer Metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Malignant Neoplasm Of Uterine Adnexa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Malignant Neoplasm Progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Metastases To Bone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Metastases To Liver</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Metastases To Lymph Nodes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Metastatic Bronchial Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Mixed Hepatocellular Cholangiocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Multiple Myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Neoplasm Malignant</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Neoplasm Skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Neuroendocrine Tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's Lymphoma Recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's Lymphoma Stage Iv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Non-Small Cell Lung Cancer Metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Oesophageal Carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Oral Fibroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Oral Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Ovarian Cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Penis Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Prostate Cancer Metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Prostate Cancer Stage Iii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Rectal Cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Salivary Gland Adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Skin Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Small Cell Lung Cancer Stage Unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma Of Skin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Undifferentiated Sarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vulval Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered State Of Consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Basal Ganglia Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Basal Ganglia Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Brain Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Carotid Artery Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" events="38" subjects_affected="33" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Carpal Tunnel Syndrome</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cerebral Artery Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cerebral Ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cerebral Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="30" subjects_affected="29" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cervical Root Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Coordination Abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Critical Illness Polyneuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's Type</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Embolic Cerebral Infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Embolic Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Facial Palsy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Guillain-Barre Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Haemorrhage Intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Intracranial Aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Ischaemic Cerebral Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Lacunar Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Metabolic Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Normal Pressure Hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Parkinson's Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Partial Seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Post-Traumatic Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Reversible Ischaemic Neurological Deficit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Speech Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Spinal Claudication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Status Epilepticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Subarachnoid Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Thoracic Outlet Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Thrombotic Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Toxic Neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Transient Global Amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vascular Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol Abuse</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Alcohol Withdrawal Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Behavioural And Psychiatric Symptoms Of Dementia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Breathing-Related Sleep Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Mood Disorder Due To A General Medical Condition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Panic Attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Psychotic Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bladder Prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bladder Tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cystitis Haemorrhagic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Nephropathy Toxic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Renal Artery Stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Renal Cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Renal Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" events="26" subjects_affected="22" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Renal Failure Chronic</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Stress Urinary Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Ureteric Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Urinary Tract Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexa Uteri Mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Balanitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cervical Polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Endometrial Hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pelvic Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Postmenopausal Haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Prostatic Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Prostatism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Uterine Polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Uterine Prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vaginal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pulmonary Oedema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bronchial Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Bronchitis Chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Epiglottic Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Laryngeal Leukoplakia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Lung Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Obstructive Airways Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pulmonary Fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pulmonary Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Respiratory Acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Respiratory Arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Sleep Apnoea Syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus Ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Dry Gangrene</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Leukoplakia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Photosensitivity Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Skin Lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Skin Necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominal Hernia Repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Aortic Aneurysm Repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Arterial Stent Insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Arteriovenous Fistula Operation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cardiac Pacemaker Battery Replacement</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Cataract Operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Central Venous Catheterisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Coronary Artery Bypass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Debridement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Ileostomy Closure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Implantable Defibrillator Replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Knee Arthroplasty</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Leg Amputation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Medical Device Change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Medical Device Removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Angioplasty</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Peripheral Revascularisation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Portal Shunt</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Renal Transplant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Toe Amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Tympanoplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vitrectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Aortic Aneurysm Rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Aortic Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Aortic Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Aortic Stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Arterial Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Arterial Haemorrhage</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Arterial Rupture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Arterial Spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Arterial Stenosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Arterial Stenosis Limb</sub_title>
                <counts group_id="E1" events="115" subjects_affected="89" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Arterial Thrombosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Arterial Thrombosis Limb</sub_title>
                <counts group_id="E1" events="76" subjects_affected="62" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis Obliterans</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Artery Dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Circulatory Collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Embolism Venous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Extremity Necrosis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Femoral Arterial Stenosis</sub_title>
                <counts group_id="E1" events="397" subjects_affected="260" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Femoral Artery Aneurysm</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Femoral Artery Dissection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Femoral Artery Embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Femoral Artery Occlusion</sub_title>
                <counts group_id="E1" events="170" subjects_affected="137" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Hypovolaemic Shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Iliac Artery Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Iliac Artery Occlusion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Iliac Artery Stenosis</sub_title>
                <counts group_id="E1" events="123" subjects_affected="95" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Iliac Artery Thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Intermittent Claudication</sub_title>
                <counts group_id="E1" events="64" subjects_affected="55" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Ischaemic Limb Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Leriche Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Lymphatic Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Necrosis Ischaemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" events="161" subjects_affected="122" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Aneurysm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Dissection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Peripheral Embolism</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="33" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Steal Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Subclavian Artery Occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Subclavian Artery Stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Subclavian Steal Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Thromboangiitis Obliterans</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Varicophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Varicose Vein</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vascular Calcification</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Venous Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Venous Stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Venous Thrombosis Limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Vessel Perforation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="287" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Femoral Arterial Stenosis</sub_title>
                <counts group_id="E1" events="175" subjects_affected="142" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Intermittent Claudication</sub_title>
                <counts group_id="E1" events="80" subjects_affected="73" subjects_at_risk="1406"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" events="85" subjects_affected="72" subjects_at_risk="1406"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kristel Wittebols Clinical Research Director</name_or_title>
      <organization>Medtronic</organization>
      <phone>+31433566580</phone>
      <email>kristel.wittebols@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

